We invest £750,000 into each SRC, providing funding for three to four years of research.
Through our SRCs we aim to:
- Create clusters of world class researchers.
- Bring researchers from different fields or disciplines together, to tackle the complex problems in cystic fibrosis.
- Widen awareness of cystic fibrosis research outside the traditional biomedical disciplines and so attract high quality investigators from new research disciplines.
- Recruit the brightest and best young researchers to cystic fibrosis research. Each SRC provides funding for five or six young scientists, who will work alongside the experts. Investing in these scientists at this stage in their careers leads to long-lasting interest in the field.
Our SRC funding so far
Since they were initiated in 2013 we have funded 14 strategic research centres. These are comprised of 96 investigators, based in over 35 institutions in 14 countries. They have attracted over 40 early career researchers to work in the field of cystic fibrosis research. Find out more about the value of our SRC programme so far on our research achievements page.
Funding SRCs is a commitment that we’ve continued into our current research strategy.
Find out how to apply
Gas, food and lodging: understanding the requirements of Pseudomonas aeruginosa in CF airways
(University of Cambridge, Technical University of Denmark, Lyngby; The Helmholz Centre for Infection Research, Braunschweig; Braunschweig University of Technology, Georgia Institute of Technology USA)
Understanding why Pseudomonas aeruginosa thrives so well in the airways of people with CF to help the design of new, more effective antibiotics
Mucociliary clearance: from fundamentals to personalised medicine
( University of Cambridge, University of North Carolina, Royal Papworth Hospital, Stanford University)
Developing and apply pioneering new methods to study the mechanics of lung clearance, as a basis for developing effective and personalised therapeutic approaches for CF in the future.
TrIFIC: Targeting Immunotherapy for Fungal Infections in Cystic Fibrosis
(Imperial College London, Queens University Belfast, University of Exeter, University Hospitals South Manchester, University of Massachusetts Medical School, Radboud University Medical School)
Understanding which immunotherapies might be effective treatments for complications of Aspergillus fumigatus infection, as alternatives to anti-fungal treatments.
Personalised approach to Pseudomonas aeruginosa (PAPA)
(Imperial College London, University of Southampton, Royal Brompton Hospital, Southampton Children's Hospital, University Hospital Southampton, University of Wollongong, Medical Detection Dogs)
Professor Jane Davies and team will be building on their work from the last SRC to investigate better ways to detect Pseudomonas aeruginosa, understand how it settles in the lungs on a strain-by-strain basis, and develop more effective drugs for treating it.
Restoring airway function in CF using alternative chloride channels
(Newcastle University, University of Utrecht, University of Regensburg, University of Lisbon)
The aim of this SRC is to understanding more about alternative targets for disease-modifying therapies in cystic fibrosis. Led by Dr Mike Gray it will build on the results of their last SRC.
The effect of gut dysbiosis on lung inflammation in cystic fibrosis
(University of Leeds, Cambridge University, Monash University, Wellcome Trust Sanger Institute, Leeds Beckett University)
This research aims to investigate exactly how levels of short chain fatty acids and antibiotics affect the bacteria in the gut of people with CF, and if this has any effect on inflammation in the lungs, as well as looking at options for amending the diet of people with CF to help return the range of gut bacteria present to a healthy balance.
Restoring fluidity in the gut
(University of Liverpool, University of Bristol, Erasmus University Medical Centre, Hannover Medical School, Sheffield Children's Hospital, University of Sheffield, Hadassah University Hospital)
Find out how researchers around the world will investigate ways to prevent blockages in the gut in people with cystic fibrosis (CF) by increasing the levels of fluid in the gut to help move digested food along more easily.
Novel therapies for Mycobacterium abscessus.
(University of Cambridge, Wellcome Trust Sanger Institute and Colorado State University)
Mycobacterium abscessus is a type of bacteria that can cause devastating lung infections in people with cystic fibrosis. It is very difficult to treat and is growing in frequency around the world. This SRC aims to use a mixture of existing expertise and cutting-edge technologies that have been developed for other purposes to develop new antibiotics and other ways of preventing and fighting this infection, and to strengthen existing treatments.
Targeting joint disease in cystic fibrosis: identifying therapeutic targets in CF arthropathy.
(Leeds Institute of Rheumatic and Musculoskeletal Medicine, University Hospitals South Manchester, St James Hospital Leeds, Lausanne University & Centre of Infection and Immunity Switzerland, Chapel Allerton Hospital Leeds, Manchester Royal Infirmary)
Cystic fibrosis-related diabetes research.
(Newcastle University, Ulster University, Lund University (Sweden), Szeged University (Hungary), Iowa University (USA)
Physical activity, exercise, sport and recreation promotion for adolescents with cystic fibrosis.
(University of Exeter, University College London, Institute of Child Health, La Trobe University, The Hospital for Sick Children (Toronto, Canada), Swansea University)
Personalised engineered cell therapies for cystic fibrosis.
(University College London, St George’s University of London, University College London, University College Cork)
Investigating the F508del-CFTR protein.
(University of Bristol, Université de Poitiers, Utrecht University, The University of Manchester and University College London)
CF-EpiNet: Harnessing data to improve lives.
(Imperial College London, University of Liverpool, University of Nottingham, London School of Hygiene and Tropical Medicine, The Hospital for Sick Children, Toronto and Norwich Medical School)
Tackling Mycobacterium abscessus infection in cystic fibrosis.
(University of Cambridge, Sanger Institute and Colorado State University)
INOVCF: Innovative non-CFTR approaches for cystic fibrosis therapy.
(Newcastle University, University of Lisbon, University of Regensburg, University of North Carolina and University of Heidelberg)
Pseudomonal infection in CF: better detection, better understanding, better treatment.
(Imperial College London, University of Amsterdam and Catholic University of the Sacred Heart, Rome)